History
Leading the way in science and innovation
2024
Production of DC-101 Active
Pharmaceutical Ingredient (API)
Pharmaceutical Ingredient (API)
- Selected for the Startup Leap
Package Support Program - Chosen for the 2024 Research and
Development Special Zone Support Project - Requested production of DC-101 Active
Pharmaceutical Ingredient (API) - Filed patents in seven countries for
“Pharmaceutical Composition for
Treating Inflammatory Diseases” - Won the Grand Prize at the 2024 Gwangju-
Jeonnam-Jeju Startup Integrated IR Camp
DC-101 Preclinical Trials in Progress
- Venture Business Certification Acquired
- Selected for the 2023 Deep Tech
TIPS Support Project (1.5 billion KRW) - Secured 300 million KRW investment from
G-Startup Technology Holding New Deal Fund - Secured 50 million KRW investment
from WP Technology Innovation Startup - Signed a service contract with
Vaxcell-Bio Co., Ltd. (80 million KRW) - Technology transfer of
“Macrophage Nano-Assembly
and Anti-Inflammatory
Composition Containing the Same” - Technology transfer of
“Tumor Microenvironment-Responsive
Nano-Composite and
Anticancer Composition Containing the Same” - Secured active pharmaceutical ingredients
(API) for radiation therapy adjuvants
2023
2022
Optimization of DC-101 Candidate Substance
- Selected for the Early Startup
Package Support Program - Selected for the Bio-Healthcare
Startup Support Program - Secured 300 million KRW in angel investment
- Secured 100 million KRW investment
from Wide & Partners - Completed preclinical toxicity testing
for radiation therapy adjuvant - Signed MOU with The Intect Co., Ltd.
Selected for the Bio-Healthcare Technology
Commercialization Support Program
Commercialization Support Program
2021
2020
Established DR.Cure Co., Ltd.
Selected for the Physician-Scientist
Innovation Support Program
by the Ministry of Science and ICT
Innovation Support Program
by the Ministry of Science and ICT
2019
